ResMed Inc . (NYSE:RMD) reported its financial results for the second quarter of fiscal year 2025, exceeding analysts' expectations with an earnings per share (EPS) of $2.43, surpassing the forecasted ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

Piper Sandler analyst Adam Maeder raised the firm’s price target on ResMed (RMD) to $260 from $252 and keeps a Neutral rating on the shares.

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.